Tempest Therapeutics Secures $4.1M in Direct Offering

The latest update is out from Tempest Therapeutics ( (TPST) ).

On June 11, 2025, Tempest Therapeutics entered into a securities purchase agreement with an institutional investor to issue and sell 405,000 shares of common stock and prefunded warrants for 334,000 shares in a direct offering. The offering, priced at $6.25 per share, is expected to generate approximately $4.1 million in net proceeds, which will support strategic alternatives, working capital, and general corporate purposes. The transaction reflects Tempest’s efforts to bolster its financial position and sustain operations into the second quarter of 2026, although the company acknowledges that its financial projections may change.

The most recent analyst rating on (TPST) stock is a Buy with a $611.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.

Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.

To see Spark’s full report on TPST stock, click here.

More about Tempest Therapeutics

Tempest Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company is engaged in advancing its pipeline of oncology products, aiming to address unmet medical needs in the market.

Average Trading Volume: 108,668

Technical Sentiment Signal: Sell

Current Market Cap: $32.7M

For a thorough assessment of TPST stock, go to TipRanks’ Stock Analysis page.